Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry-Reference-Cited by-同舟云学术

Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry

Published:2020-09 Issue:5 Volume:16 Page:469-480
ISSN:1479-6678
Container-title:Future Cardiology
language:en
Short-container-title:Future Cardiology

Author:

Barón-Esquivias Gonzalo¹,Roldán Rabadán Inmaculada²,García Quintana Antonio³,Cerezo Manchado Juan José⁴,Antorrena Miranda Isabel²,Gómez-Barrado José Javier⁵,Pérez Paredes Matías⁶,Santas Enrique⁷,Pindado Rodríguez Javier⁸,Muñoz-Robles Jorge Andrés⁹,Oliver-Miñarro Desamparados⁹,Santamaría Amparo¹⁰,

Affiliation:

1. Cardiology Service, Hospital Universitario Virgen del Rocío, Sevilla, Spain

2. Cardiology Service, Hospital Universitario La Paz, Madrid, Spain

3. Cardiology Service, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain

4. Hematology service, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain

5. Cardiology Service, Hospital Universitario San Pedro de Alcántara, Cáceres, Spain

6. Cardiology Service, Hospital General Universitario Morales Meseguer, Murcia, Spain

7. Cardiology Service, Hospital Clínico Universitario, Valencia, Spain

8. Cardiology Service, Hospital Universitario de Álava, Spain

9. Medical Department, Daiichi Sankyo España, Madrid, Spain

10. Hematology service, Hospital Universitario del Vinalopó, Torrevieja, Spain

Abstract

Aim: To ascertain the clinical profile and management of edoxaban in clinical practice. Materials & methods: Prospective, noninterventional postauthorization study of nonselected patients with atrial fibrillation treated with edoxaban from 12 European countries. Patients’ baseline characteristics are presented. Results: A total of 13,638 patients (73.6 ± 9.5 years; 76.6/23.4% edoxaban 60/30 mg; CHA2DS2-VASc 3.1; 838 [6.1%] from Spain) were included. In Spain, the percentage of very elderly and fragile patients was greater and the risk of thromboembolism (CHA2DS2-VASc ≥2, 98.0 vs 87.3%; p < 0.001) and bleeding (HAS-BLED, 3.2 vs 2.7; p < 0.001) was greater in patients treated with edoxaban 30 mg. The proportion of patients taking edoxaban 30 mg was similar than in ENGAGE AF-TIMI 48. Conclusion: In Spain, patients treated with edoxaban were older and fragile.

Publisher

Future Medicine Ltd

Subject

Cardiology and Cardiovascular Medicine,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fca-2020-0024

Reference27 articles.

1. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2. Pacientes con fibrilación auricular asistidos en consultas de atención primaria. Estudio Val-FAAP

3. The Costs of Warfarin Underuse and Nonadherence in Patients with Atrial Fibrillation: A Commercial Insurer Perspective

4. Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing

5. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Seguridad y efectividad del edoxabán en la práctica clínica tras un año de seguimiento en España. Registro ETNA-AF-EUROPE;REC: CardioClinics;2022-01

2. Prevención del ictus en pacientes con fibrilación auricular. Mejorar la protección enla era de la COVID-19;Revista Española de Cardiología Suplementos;2021